Stem cells that have been specifically developed for use as clinical therapies are fit for use in patients, an independent study of their genetic make-up suggests. The research – which focused on human embryonic stem cells – paves the way for clinical trials of cell therapies to treat conditions such as Parkinson’s disease, age-related degeneration of the eyes and spinal cord injury.
An estimated seven to ten million people worldwide are living with Parkinson’s disease (PD), which is an incurable and progressive disease of the nervous system affecting movement and cognitive function. More than half of PD patients develop progressive disease showing signs of dementia similar to Alzheimer’s disease.
As a potential treatment for Parkinson’s disease, scientists at the University of North Carolina at Chapel Hill have created smarter immune cells that produce and deliver a healing protein to the brain while also teaching neurons to begin making the protein for themselves.
Scientists in Japan have have discovered how nerve cells adjust to low energy environments during the brain’s growth process. Their study may one day help find treatments for nerve cell damage and neurodegenerative disorders such as Alzheimer’s and Parkinson’s diseases.